{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:09Z","timestamp":1788966069348,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Several conflicting reviews have concluded that the use of loop diuretics is associated with poorer clinical and safety outcomes. Therefore, this study aimed to investigate the efficacy and safety of tolvaptan as an adjunct to conventional diuretic therapy in patients with acute heart failure (AHF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search was conducted on PubMed, Embase, ProQuest, EBSCO, and Cochrane Library until 24 May 2023 to identify randomized controlled trials that compared the effects of tolvaptan with conventional therapy and placebo in patients with AHF. The quality assessment of the included trials was conducted using the Cochrane risk of bias. A network meta-analysis (NMA) was conducted to examine the dosage effect of tolvaptan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>A total of 17 studies with 18 reports, involving 10,039 patients, were selected. The tolvaptan add-on therapy significantly alleviated dyspnea [24\u2005h: RR 1.16 (1.04, 1.29), 48\u2005h: RR 1.18 (1.04, 1.33)], reduced body weight within 48\u2005h [Asian group, MD \u22120.93 (\u22121.48, \u22120.38); non-Asian group, MD \u22122.76 (\u22122.88, \u22122.65)], reduced edema [RR 1.08 (1.02, 1.15)], increased serum sodium [non-Asian group, MD 3.40 (3.02, 3.78)], and resulted in a change in serum creatinine [MD \u22120.10 (\u22120.18, \u22120.01)]. No significant differences were observed in mortality and rehospitalization. The NMA suggested that an intermediate dosage (15\u2005mg\/day) might offer the best efficacy in reducing dyspnea within 24\u2005h, reducing edema, increasing serum sodium, and lowering the incidence of worsening renal function (WRF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, the meta-analysis showed that tolvaptan contributed to the short-term alleviation of congestive symptoms, elevated sodium levels, and a lower incidence of WRF. However, no significant benefits were observed in long-term symptoms, rehospitalization rates, and mortality. An intermediate dosage of tolvaptan might be considered the optimal choice for various clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/<\/jats:ext-link>, PROSPERO (CRD42023420288).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1367442","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T04:49:55Z","timestamp":1717044595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Vireza","family":"Pratama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Budiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarir At","family":"Thobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bambang","family":"Widyantoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita Yanti","family":"Anggraeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Kris","family":"Dinarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ejhf.1502","article-title":"Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes","volume":"21","author":"Javaloyes","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10741-018-9735-7","article-title":"Loop diuretics in chronic heart failure: how to manage congestion?","volume":"24","author":"Simonavi\u010dius","year":"2019","journal-title":"Heart Fail Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ihj.2021.12.003","article-title":"Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure","volume":"74","author":"Kansara","year":"2022","journal-title":"Indian Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.6515\/ACS.202211_38(6).20220422A","article-title":"The efficacy and safety of short-term tolvaptan usage in patients with acute decompensated heart failure","volume":"38","author":"Lin","year":"2022","journal-title":"Acta Cardiol Sin"},{"key":"B6","first-page":"50","article-title":"Benefit of add on low dose oral tolvaptan to loop diuretics among patients with acute decompensated heart failure: randomized controlled trial","volume":"28","author":"Chitthai","year":"2022","journal-title":"J Nephrol Soc Thail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/ehf2.12783","article-title":"Tolvaptan vs. furosemide based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF)","volume":"7","author":"Ng","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","article-title":"Effects of additive tolvaptan vs. Increased furosemide on heart failure with diuretic resistance and renal impairment\u2014results from the K-STAR study","volume":"82","author":"Inomata","year":"2017","journal-title":"Circ J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction\u2014prospective randomized controlled study","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ihj.2015.07.006","article-title":"Effect of tolvaptan on acute heart failure with hyponatremia\u2014a randomized, double blind, controlled clinical trial","volume":"68","author":"Shanmugam","year":"2016","journal-title":"Indian Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure","volume":"67","author":"Kimura","year":"2016","journal-title":"J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","article-title":"Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.02.016","article-title":"A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis","volume":"157","author":"Nevill","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4070\/kcj.2018.0125","article-title":"Acute heart failure management","volume":"48","author":"\u010cerlinskait\u0117","year":"2018","journal-title":"Korean Circ J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"783181","DOI":"10.3389\/fcvm.2021.783181","article-title":"Tolvaptan add-on therapy to overcome loop diuretic resistance in acute heart failure with renal dysfunction (DR-AHF): design and rationale","volume":"8","author":"Minh","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/IJNRD.S7032","article-title":"Tolvaptan, hyponatremia, and heart failure","volume":"4","author":"Zmily","year":"2011","journal-title":"IntJ Nephrol Renovasc Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s11936-011-0149-2","article-title":"Update on the management of acute decompensated heart failure","volume":"13","author":"Majure","year":"2011","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.36011\/cpp.2021.3.e3","article-title":"Vasopressin receptor antagonist, tolvaptan, for treating hyponatremia in patients with heart failure","volume":"3","author":"Kim","year":"2021","journal-title":"Cardiovasc Prevent Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e001173","DOI":"10.1136\/openhrt-2019-001173","article-title":"Renal kinetics in acute heart failure","volume":"7","author":"Nhat","year":"2020","journal-title":"Open Heart"},{"key":"B30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/0886022X.2020.1858100","article-title":"Any heart failure treatments associated with worsening renal function in patients admitted due to acute heart failure?","volume":"43","author":"Limkunakul","year":"2021","journal-title":"Ren Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ehf2.12264","article-title":"Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure","volume":"5","author":"Shirakabe","year":"2018","journal-title":"ESC Heart Failure"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jacc.2012.01.077","article-title":"Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure","volume":"60","author":"Ronco","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11897-017-0319-y","article-title":"Diuretic strategies in acute decompensated heart failure","volume":"14","author":"Hardin","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.4330\/wjc.v6.i12.1252","article-title":"Arginine vasopressin as a target in the treatment of acute heart failure","volume":"6","author":"Gilotra","year":"2014","journal-title":"World J Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3760\/cma.j.issn.0253-3758.2018.10.004","article-title":"Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018","volume":"46","year":"2018","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure\u2014digest version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"B38","first-page":"231","article-title":"Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: introduction and diagnosis","volume":"102","author":"Ariyachaipanich","year":"2019","journal-title":"J Med Assoc Thail"},{"key":"B39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.12688\/wellcomeopenres.16336.1","article-title":"Cardiovascular disease risk and pathophysiology in South Asians: can longitudinal multi-omics shed light?","volume":"5","author":"Sun","year":"2020","journal-title":"Wellcome Open Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.21037\/atm-2022-54","article-title":"Does race\/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes? A comparison between Asian versus white patients","volume":"10","author":"Scheen","year":"2022","journal-title":"Ann Transl Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e00614","DOI":"10.1002\/prp2.614","article-title":"Tolvaptan add-on therapy in patients with acute heart failure: a systematic review and meta-analysis","volume":"8","author":"Luo","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1253\/circj.CJ-17-0986","article-title":"Novel risk score efficiently prevents tolvaptan-induced hypernatremic events in patients with heart failure","volume":"82","author":"Kinugawa","year":"2018","journal-title":"Circ J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1367442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T04:50:20Z","timestamp":1717044620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1367442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":42,"alternative-id":["10.3389\/fcvm.2024.1367442"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1367442","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1367442"}}